文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Aficamten对梗阻性肥厚型心肌病疾病与症状负担的影响:SEQUOIA-HCM研究结果

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
PubMed 文献 · J Am Coll Cardiol · 2024-09-30

SEQUOIA-HCM是一项3期随机对照试验,评估Aficamten(心肌肌球蛋白抑制剂)对症状性梗阻性肥厚型心肌病(oHCM)患者的疗效。结果显示Aficamten在改善症状、血流动力学、运动能力和降低NT-proBNP方面均显著优于安慰剂,且更多患者不再符合室间隔减容治疗指征。

要点

  • Aficamten治疗24周显著改善oHCM患者症状、血流动力学、运动能力和NT-proBNP。
  • Aficamten组97%患者至少一项结局指标改善,23%达到全部四项,安慰剂组为59%和0%。
  • Aficamten组88%患者不再符合室间隔减容治疗指征,安慰剂组为52%。

核心结论

  • Aficamten治疗症状性oHCM患者在多个临床相关疗效指标上均带来显著改善。
  • Aficamten可能广泛用于症状性oHCM的治疗。

研究设计与样本

  • SEQUOIA-HCM为3期随机对照试验,纳入症状性oHCM患者,随机接受Aficamten(n=142)或安慰剂(n=140)每日治疗24周。

主要发现

  • 24周时,Aficamten组与安慰剂组分别有71%和42%患者限制性症状改善(P≤0.002)。
  • Aficamten组与安慰剂组分别有68%和7%患者达到完全血流动力学应答(P≤0.002)。
  • Aficamten组与安慰剂组分别有47%和24%患者运动能力提升(P≤0.002)。
  • Aficamten组与安慰剂组分别有84%和8%患者NT-proBNP降低≥50%(P≤0.002)。
  • Aficamten组97%患者至少一项结局改善(安慰剂组59%),23%达到全部四项(安慰剂组0%)。

关键数值与推荐

  • 完全血流动力学应答定义为静息和Valsalva梯度分别<30 mm Hg和<50 mm Hg。
  • 限制性症状改善定义为NYHA功能分级改善≥1级和/或KCCQ-CSS评分变化≥10分。
  • 运动能力提升定义为峰值摄氧量变化≥1.5 mL/kg/min。
  • NT-proBNP降低≥50%为另一项结局指标。

临床怎么用

  • Aficamten可用于症状性oHCM患者,改善症状、血流动力学、运动能力和生物标志物。
  • Aficamten治疗可能降低患者对室间隔减容治疗的需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aficamten is a cardiac myosin inhibitor that mitigates left ventricular outflow gradients in obstructive hypertrophic cardiomyopathy (oHCM). The clinical efficacy of aficamten across multiple outcome domains in oHCM has not been fully defined. OBJECTIVES: This responder analysis from the SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM) trial characterizes the clinical impact of aficamten. METHODS: Patients who were symptomatic of oHCM were randomized to aficamten (n = 142) or placebo (n = 140) daily for 24 weeks. Outcomes assessed included the proportion of patients with complete hemodynamic response (rest and Valsalva gradient <30 mm Hg and <50 mm Hg, respectively), relief in limiting symptoms (≥1 improvement in NYHA functional class and/or ≥10-point change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score), enhanced exercise capacity (≥1.5 mL/kg/min change in peak oxygen uptake), and ≥50% reduction in N-terminal pro-B-type natriuretic peptide. Eligibility for septal reduction therapy was also evaluated. RESULTS: At 24 weeks, patients treated with aficamten vs placebo showed significant improvement in limiting symptoms (71% vs 42%), were more likely to have complete hemodynamic response (68% vs 7%), demonstrated enhanced exercise capacity (47% vs 24%), and showed a decrease ≥50% in N-terminal pro-B-type natriuretic peptide (84% vs 8%) (P ≤ 0.002 for all). An improvement in ≥1 of these outcome measures was achieved in 97% of patients treated with aficamten (vs 59% placebo), including 23% on aficamten who achieved all 4 outcomes compared with none in placebo. Among 32 patients receiving aficamten and 29 patients receiving placebo who were eligible for septal reduction therapy, 28 (88%) from the aficamten group were no longer eligible at 24 weeks compared with 15 (52%) from the placebo group (P = 0.002). CONCLUSIONS: Treatment with aficamten was associated with substantial improvements across a broad range of clinically relevant efficacy measures. These results underscore the wide-ranging potential of aficamten for treatment of patients with symptomatic oHCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with oHCM [SEQUOIA-HCM]; NCT05186818).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Maron MS, Masri A, Nassif ME, et al. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Coll Cardiol. 2024. PMID: 39352339. doi:10.1016/j.jacc.2024.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。